Premium
The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis
Author(s) -
IRVINE E. J.,
YEH C.H.,
RAMSEY D.,
STIRLING A. L.,
HIGGINS P. D. R.
Publication year - 2008
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2008.03854.x
Subject(s) - mesalazine , medicine , ulcerative colitis , quality of life (healthcare) , inflammatory bowel disease , gastroenterology , randomized controlled trial , clinical trial , colitis , disease , nursing
Summary Background Ulcerative colitis (UC) has a major impact on the quality of life (QoL) of affected patients. Patient‐reported outcomes have not been thoroughly evaluated in patients with UC receiving oral mesalazine (mesalamine). Aim To examine the effect of mesalazine on QoL of patients with mildly and moderately active UC and assess the time course of change, baseline disease severity, mesalazine dose and responder status on QoL parameters. Methods Inflammatory Bowel Disease Questionnaire (IBDQ) data were combined from two double‐blind, randomized, multicentre, active‐controlled trials assessing 2.4 and 4.8 g/day oral delayed‐release mesalazine in 687 patients. Mean score changes from baseline were compared at 3 and 6 weeks and effects of baseline severity, mesalazine dose and response to therapy were examined. Results Mesalazine significantly improved IBDQ scores at 3 and 6 weeks (mean increase, 29.6 and 39.7 points, respectively; P < 0.0001 for both). Improvement was greater for patients with moderate disease. Greater week 6 changes occurred in clinical responders than nonresponders (50.1 vs. 23.6 points, respectively; P < 0.0001). Conclusions Delayed‐release oral mesalazine produces significant clinical and statistical improvements in QoL of patients with UC by 3 weeks, with further improvement at 6 weeks.